Is GLP-l (9-36)amide an endogenous antagonist at GLP-l receptors?

DOD

Discussions

Biomedical Jobmarket

News

DOD Alert

Edit DOD

ACCOUNT

Forgotten Password?


Diabetes OD > Development and Function of Pancreas and Immunity > Pancreas > Incretin Hormones > GLP-1 > Journal Article

(Journal Article): Is GLP-l (9-36)amide an endogenous antagonist at GLP-l receptors?

Grandt D, Sieburg B, Sievert J,

IN: Digestion 1994; 55:302.-
Impact Factor(s) of Digestion: 1.473 (2004), 1.672 (2002), 1.89 (2001)

ABSTRACT: n.a.

TYPE OF PUBLICATION: Original article

Articles citing this article:

Deacon CF, Johnsen AH, Holst JJ. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab 1995. 80: 952-957.
» Diabetes OD » Disease Management » T2DM » Metabolic Control » Anti-Hyperglycemic and Anti-Ap... » Incretin Hormones » GLP-1 » Effectivity of GLP-1 in Therap... » Degradation by Dipeptidyl Pept... » Journal Article

Respond on this Journal Article! Hint: Your Response should directly apply to *Is GLP-l (9-36)amide an endogenous antagonist at GLP-l receptors?. Please check, if this context applies best to your contribution. Otherwise click HERE* to change to the appropriate subject area. The actual subject area is GLP-1.

About DOD | Advertising Information | Support The Project | DOD alert | Become Editor